Key result
18F-FDG PET demonstrates 100% sensitivity for detecting adrenal metastases in bronchogenic carcinoma.
Why the study?
The usefulness of 18F-fluorodeoxyglucose PET in differentiating benign from metastatic adrenal masses in patients with bronchogenic carcinoma was assessed.
Does 18F-FDG PET accurately differentiate benign from metastatic adrenal masses in patients with bronchogenic carcinoma?
Comparison
18F-fluorodeoxyglucose PET vs biopsy and CT findings
Design
Prospective observational study with independent review by three radiologists
Authors
Loading...
FDG-PET offers high sensitivity for metastatic adrenal lesions in lung cancer; leaves open whether specificity supports routine biopsy avoidance.
Observational (n=27)
No
Does 18F-FDG PET accurately differentiate benign from metastatic adrenal masses in patients with bronchogenic carcinoma?
18F-FDG PET is a highly sensitive and reasonably specific noninvasive method for differentiating benign from metastatic adrenal masses in patients with bronchogenic carcinoma.
Erasmus et al. (1997) conducted an observational in Bronchogenic carcinoma with an adrenal mass (n=27). 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) vs. Biopsy and CT findings was evaluated on Sensitivity and specificity for detecting metastatic disease to the adrenal gland. 18F-FDG PET demonstrated 100% sensitivity and 80% specificity for detecting metastatic disease to the adrenal gland in patients with bronchogenic carcinoma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: